Dopamine receptor agonist potencies for inhibition of cell firing correlate with dopamine D 3 receptor binding affinities

By Kreiss D.S.   Bergstrom D.A.   Gonzalez A.M.   Huang K.-X.   Sibley D.R.   Walters J.R.  

European Journal of Pharmacology, Vol. 277, Iss. 2, 1995-04 ,pp. : 209-214

Elsevier

Access to resources Recommend Favorite

Effects of the D 3 preferring dopamine agonist pramipexole on sleep and waking, locomotor activity and striatal dopamine release in rats

By Lagos P.   Scorza C.   Monti J.M.   Jantos H.   Reyes-Parada M.   Silveira R.   Ponzoni A.  

European Neuropsychopharmacology, Vol. 8, Iss. 2, 1998-05 ,pp. : 113-120

Elsevier

Access to resources Recommend Favorite

The behavioural effects of pramipexole, a novel dopamine receptor agonist

By Maj J.   Rogoz Z.   Skuza G.   Kolodziejczyk K.  

European Journal of Pharmacology, Vol. 324, Iss. 1, 1997-04 ,pp. : 31-37

Elsevier

Access to resources Recommend Favorite

Evidence for antagonist activity of the dopamine D3 receptor partial agonist, BP 897, at human dopamine D3 receptor

By Wood M.D.   Boyfield I.   Nash D.J.   Jewitt F.R.   Avenell K.Y.   Riley G.J.  

European Journal of Pharmacology, Vol. 407, Iss. 1, 2000-10 ,pp. : 47-51

Elsevier

Access to resources Recommend Favorite

The dopamine D3 receptor partial agonist, BP 897, is an antagonist at human dopamine D3 receptors and at rat somatodendritic dopamine D3 receptors

By Wicke K.   Garcia-Ladona J.  

European Journal of Pharmacology, Vol. 424, Iss. 2, 2001-07 ,pp. : 85-90

Elsevier

Access to resources Recommend Favorite